# Trial of Docetaxel and Irinotecan (DI) for Recurrent or Refractory Bone and Soft Tissue Sarcomas.

> **NCT01380275** · PHASE2 · UNKNOWN · sponsor: **National Cancer Center, Korea** · enrollment: 35 (estimated)

## Conditions studied

- Sarcoma

## Interventions

- **DRUG:** Docetaxel (Taxotere)
- **DRUG:** Irinotecan

## Key facts

- **NCT ID:** NCT01380275
- **Lead sponsor:** National Cancer Center, Korea
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2008-04
- **Primary completion:** 2014-09
- **Final completion:** 2014-12
- **Target enrollment:** 35 (ESTIMATED)
- **Last updated:** 2014-09-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01380275

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01380275, "Trial of Docetaxel and Irinotecan (DI) for Recurrent or Refractory Bone and Soft Tissue Sarcomas.". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT01380275. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*